已阅读5页,还剩33页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
李 勇 复旦大学华山医院心脏科,心力衰竭临床药物治疗面临的挑战,Acute Infarction (hours),Infarct Expansion (hours to days),Global Remodeling (days to months),心肌梗死后左心室重构,交感神经 RAAS,交感神经 RAAS,交感神经 RAAS,血液动力学的变化 (CO、LVEDP),心力衰竭临床症状的基础,心室重塑 (心室结构、功能的变化),心力衰竭发生发展的基础,ACEI治疗心力衰竭 病死率和病残率,0 5 10 15 20 25 30 35 40 45 50,危险度降低(),心衰死亡率或住院率,总死亡率,心衰死亡率,致命性/非致命性心梗,0.001 35%,0.001 23%,0.001 31%,0.04 20%,Garg R,Yusuf S.JAMA.1995;237:1450-1456.,-阻滞剂治疗心力衰竭:无可辩驳的证据,34% ,Cumulative Mortality (%),Days,20,15,5,0,10,P=.0062 (adjusted),Metoprolol CR/XL (n=1990),Placebo (n=2001),US Carvedilol Trials1,Probability of Event-free Survival,Carvedilol (n=696),Placebo (n=398),Days,P.001,0.0,0,100,200,300,400,65% ,1.0,0.8,0.7,0.9,MERIT-HF2,Survival (% of Patients),100,90,80,60,70,0,600,0,400,300,200,100,Days,Carvedilol (n=1156),Placebo (n=1133),500,600,0,400,300,200,100,500,35% ,P=.00013,COPERNICUS4,Days,0.0,200,400,800,1.0,0.8,0.6,P.0001,34% ,Bisoprolol (n=1327),Placebo (n=1320),CIBIS-II3,0,600,Survival,1. Packer M et al. N Engl J Med. 1996;334:13491355. 2. MERIT-HF Study Group. Lancet. 1999;253:20012007. 3. CIBIS-II Investigators. Lancet. 1999;353:913. 4. Packer M et al. N Engl J Med. 2001;344:16511658.,0,1,2,3,年,0,10,20,30,40,50,3.5,风险比值 0.85 (95% CI 0.75-0.96), p=0.011 校正风险比值 0.85, p=0.010,483 (37.9%),538 (42.3%),%,NNT = 23,1 年 HR 0.76 P0.001,CHARM - 合用组:首要终点,心血管死亡或心衰住院的比例(%),安慰剂,坎地沙坦,有危险的例数 坎地沙坦 1276 1176 1063 948 457 安慰剂 1272 1136 1013 906 422,心率:心血管死亡的预测因子,Fox K et al. Lancet Online August 31, 2008.,心率 70 bpm,心率 70 bpm,Change in heart rate (bpm),Change in mortality (%),-20,-16,-12,-8,-4,0,4,8,12,-100,-80,-60,-40,-20,0,20,40,60,PROFILE,PROMISE,XAMOTEROL,VHeFT (Prazosin),VHeFT (HDZ/ISDN),CONSENSUS,SOLVD,US CARVEDILOL,MOCHA,CIBIS,NOR TIMOLOL,BHAT,ANZ,*,*,GESICA,Change in Heart Rate and CHF Mortality,Kjekshus & Gullestad (1999),总死亡率,随访月,百分比,安慰剂,美托洛尔,p = 0.0096,安慰剂,美托洛尔,p = 0.0067,降低危险 = 36%,百分比,低剂量组 每3个月随访 (n=1016),高剂量组 每3个月随访 (n=2635),随访月,MERIT-HF: 3个月后剂量相关的回顾性亚组分析,Wikstrand J et al. for the MERIT-HF Study Group.,4周 (41mg),6周 (80mg),8周 (151mg),基线,基线,2周 (21mg),2周 (17mg),4周 (32mg),6周 (64mg),8周与 3月 (76mg),(次/分),美托洛尔控释片剂量,65,70,75,80,85,0,50,100,150,200,MERIT-HF: 3个月后剂量相关的回顾性亚组分析,3 月 (192mg),小剂量组,大剂量组,Wikstrand J et al. for the MERIT-HF Study Group.,心率减慢,Incomplete follow-up 102 withdrew consent 3 randomisation irregularities,Incomplete follow-up 114 withdrew consent 1 lost to follow-up,Patients and follow-up,10 917 randomised,5479 to ivabradine,5438 to placebo,Median study duration: 19 months; maximum: 35 months,5438 analysed,5479 analysed,12 138 screened,Study design,Ivabradine 5 mg 7.5 mg twice daily,Matching placebo,Visits,Am Heart J. 2006;152:860-66,Treatment Target HR60 bpm Reduce dosage or discontinue when HR50bpm or/and symptomatic bradycardia,选择性窦房结If通道阻滞剂对心率的影响, 总体人群, HR 70 bpm人群,伊伐布雷定平均剂量: 6.18 mg bid,Fox K et al. Lancet Online August 31, 2008.,伊伐布雷定平均剂量: 6.64 mg bid,心肌梗死后静息心率减慢与临床获益,Cucherat M. Euro Heart J, 2007; 28: 30123019.,选择性窦房结If通道阻滞剂对主要终点的影响,主要复合终点:心血管死亡、因急性心肌梗死住院、因心力衰竭新发或恶化而住院,Fox K et al. Lancet Online August 31, 2008., 总体人群, HR 70 bpm人群,患者基线时的治疗,Fox K et al. Lancet Online August 31, 2008.,RRR 30,RRR 42,Olsson G et al. Am J Hypertens 1991;4(2 Pt 1):151-158. Olsson G et al.Eur Heart J 1992;13:28-32. The MERIT-HF Study Group. Lancet 1999;353:2001-2007.,1阻滞剂:有效降低心脏性猝死危险,RRR 41,心力衰竭患病率,66-103,75-86,70-84,75,50,40,25,55-95,78,76,75,60,68,65,年龄段,平均年龄,美国 (CHS),芬兰(Helsinki),英国(Poole),丹麦. (Copen.),西班牙 (Asturias),葡萄牙(EPICA),荷兰 (Rotter.),瑞典(Vasteras),左心室收缩功能降低的比例,HF-PSF的比例,55,51,68,46,71,59,39,71,Petrie M, McMurray J. Lancet. 2001;358:423-434. Hogg K et al. J Am Coll Card. 2004;43:317-327.,CHF患病率 (%),0,1,2,3,4,5,6,7,8,9,10,心力衰竭患者中HF-PEF的比例,EF 50%,EF 45%,EF 50%,EF 50%,Framingham2 (n=73),Olmstead1 (n=137),CHS3 (n=269),NHF Project4 (n=19,710),1. Senni M et al. Circulation. 1998;98:2282-2289. 2. Vasan RS et al. J Am Coll Card. 1999;33:1948-1955. 3. Gottdiener JS et al. Ann Intern Med. 2002;137:631-639.,EF 50%,EF 50%,Owan5 (n=4,596),Bhatia6 (n=2,802),Patients (%),4. Masoudi FA et al. J Am Coll Card. 2003;41-217-223. 5. Owan TE et al. N Engl J Med. 2006;355:251-259. 6. Bhatia RS et al. N Engl J Med. 2006;355:260-269.,HF-PEF患病趋势,Owan TE et al. N Engl J Med. 2006;355:251-259.,SHF与HF-PEF的预后(5年生存率) OWAN TE et al. N Engl J Med 2006; 355: 251-259,射血分数正常的患者,射血分数降低的患者,危险病例数,危险病例数,年,年,生存率,生存率,Placebo,Forced titration,Maintenance,Enrollment,Single-blind 2 weeks,W 2,W 4,W 8,M 6,M 10,M 14 to end Every 4 months,75 mg,150 mg,300 mg,Follow-up continued until 1,440 primary endpoints occurred,N=4,128,I-PRESERVE: Study Design,Irbesartan,R,Only 1/3 pts could enter on an ACEI,Randomized, double-blind, placebo controlled trial,I-PRESERVE: Primary Endpoint Death or protocol specified CV hospitalization (Mean follow-up 49.5 months),Months from Randomization,Cumulative Incidence of Primary Events (%),40 -,0 -,10 -,20 -,30 -,0,6,12,18,24,36,42,30,48,60,54,2067,1929,1812,1730,1640,1513,1291,1569,1088,497,816,2061,1921,1808,1715,1618,1466,1246,1539,1051,446,776,No. at Risk,Irbesartan,Placebo,HR (95% CI) = 0.95 (0.86-1.05) Log-rank p=0.35,I-PRESERVE: Baseline Treatments,32,30,Lipid lowering,59,58,Antiplatelet,40,39,Calcium channel blocker,59,58,Beta-blocker,14,13,Digoxin,26,25,ACE-inhibitor,15,15,Spironolactone,82,84,Treatment (%) Diuretic,Irbesartan (N = 2067),Placebo (N = 2061),38,39,27,28,Total exposed during the study,72,72,Adapted with permission from: Vasan RS, Levy D. Arch Intern Med. 1996;156:1790.,Progression From Hypertension to LVH, CAD, and Heart Failure,HTN,Smoking Lipids Diabetes,Obesity Diabetes Insulin Resistance,MI,LVH,Normal Left Ventricular (LV) Structure and Function,LV Remodeling,Subclinical LV Dysfunction,Overt HF,Diastolic Dysfunction,Systolic Dysfunction,CHF,CAD,V-HeFT: 血浆去甲肾上腺素水平与病死率的关系,累计死亡率(%),月,NE 900pg/ml NE 600-900 NE600pg/ml,100,80,60,40,20,0,0,12,24,36,48,60,总 体 P0.0001,BNP (pg/ml),41,4197,98238,238,BNP,随机化后时间 (月),生存率,9.7,14.3,20.7,32.4,% 死亡率,NE,572,274,274394,395572,NE (pg/mL),24.2,% 死亡率,13.8,16.5,23.0,Val-HeFT: BNP和NE基线四分法全因死亡率亚组分析,20,10,30,0,40,Anand IS. Circulation. 2003;107:12781283.,随机化后时间 (月),Heart Failure after MI and HTN Systolic vs Diastolic,N Engl J Med 2003;348:2007-18,高血压-左心室肥厚-交感神经活性,高血压 交感神经活性 RAAS活性,心率 X 每搏量 = 心输出量,心肌细胞肥大,细胞外基质堆积,心输出量,左心室壁肥厚,室腔容积减小,每搏量,舒张时间间期缩短,每搏量,药物对肾素血管紧张素系统的作用,血管紧张素原,肾素,Ang I,AT1 受体,Ang II,ACEI (yes) BB (yes),15.5,1.1,7.2,Ang II (fmol/mL),(n = 11),ACEI (yes) BB (no),(n = 11),101,5,10,20,15,100,95,Ang I (fmol/mL),5,10,20,15,100,95,血管紧张素 II,血管紧张
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 租客有老人小孩租房合同(2篇)
- 巜赵州桥 课件
- 西南林业大学《茶艺》2023-2024学年第一学期期末试卷
- 西京学院《设计表现》2023-2024学年第一学期期末试卷
- 探究水温对金鱼呼吸的影响
- 新人教版五年级上册用字母表示数例3教程
- 西京学院《工程力学》2023-2024学年第一学期期末试卷
- 西京学院《安装工程计量与计价》2021-2022学年第一学期期末试卷
- 西华师范大学《数字电子技术基础》2022-2023学年期末试卷
- 描写眼睛 课件
- 中医知识:产后头痛
- 住院医师规范化培训临床小讲课指南(2021年版)
- 执行实务一百问
- 成人癌性疼痛护理-中华护理学会团体标准2019
- 吊篮作业安全措施
- 《思想道德与法治》2021版第四章
- 找出划线部分读音不同的单词
- 产品销售培训心得
- 精神分裂症的规范化治疗讲课课件
- 二年级下册道德与法治教案-3.2节约粮食北师大版
- 急诊剖宫产分级
评论
0/150
提交评论